Clinical effect of labetalol combined with nifedipine on essential hypertension and its influence on inflammatory factor and coagulation function
10.3760/cma.j.issn.1008-6706.2020.10.004
- VernacularTitle:拉贝洛尔联合硝苯地平治疗原发性高血压临床疗效观察及对患者炎性因子和凝血功能的影响
- Author:
Xinmei NI
1
;
Lilin LU
Author Information
1. 浙江省荣军医院药剂科，嘉兴 314000
- From:
Chinese Journal of Primary Medicine and Pharmacy
2020;27(10):1168-1172
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical efficacy of labetalol combined with nifedipine in the treatment of patients with essential hypertension and its influence on inflammatory factors and coagulation function.Methods:From December 2017 to December 2018, 142 patients with essential hypertension admitted to Rongjun Hospital of Zhejiang Province were divided into control group (71 cases) and observation group (71 cases) according to random number table method.The patients in the control group were treated with nifedipine, while patients in the observation group were treated with labetalol on the basis of the control group.Both two groups were treated for 3 months.The therapeutic effect, changes of blood pressure, inflammatory factors, coagulation function and adverse reactions were compared between the two groups before and after treatment.Results:The total effective rate of the observation group (90.14%) was higher than that of the control group (73.24%) (χ 2=6.780, P<0.05). After treatment, the diastolic blood pressure(DBP) and systolic blood pressure(SBP) in the two groups were lower than those before treatment (observation group: t=24.544, 19.890, control group: t=14.473, 19.273, all P<0.05). After treatment, the DBP and SBP in the observation group were lower than those in the control group ( t=8.756, 6.892, all P<0.05). After treatment, the serum levels of IL-6, C-reactive protein (CRP) and TNF-α in the two groups were lower than those before treatment (observation group: t=15.125, 20.859, 22.729, control group: t=7.784, 10.865, 10.418, all P<0.05). After treatment, the serum levels of IL-6, CRP and TNF-α in the observation group were lower than those in the control group ( t=15.145, 7.662, 13.692, all P<0.05). After treatment, the plasma D-dimer and Fib levels in the two groups were lower than before treatment (observation group: t=14.655, 18.707, control group: t=8.728, 7.269, all P<0.05). After treatment, the plasma D-dimer and Fib levels in the observation group were lower than those in the control group ( t=9.384, 10.831, all P<0.05). There was no statistically significant difference in adverse reactions between the two groups ( P>0.05). Conclusion:Labetalol combined with nifedipine has good clinical efficacy in treating essential hypertension, alleviating inflammation and improving coagulation function, which is worthy of clinical reference.
